登革热疫苗接种对血清学诊断的影响:来自III期登革热疫苗效力试验的见解
对两项III期安慰剂对照CYD-TDV疫苗效力试验中发热事件进行事后汇总分析,涉及亚洲和拉丁美洲10个国家≥31000名2-16岁儿童。病毒学确诊登革热1284例(疫苗组575例,安慰剂组709例),其他发热事件17673例(疫苗组11668例,安慰剂组6005例)。可能登革热定义的敏感性和特异性分别为93.1%和77.2%,总体阳性预测值和阴性预测值分别为22.9%和99.5%。接种疫苗诱导的假阳性诊断偏倚在基线血清阴性个体中更为明显。
要点
- 可能登革热血清学定义敏感性93.1%、特异性77.2%,总体阳性预测值22.9%、阴性预测值99.5%。
- 接种CYD-TDV后常规监测中获得的IgM和IgG数据解读需谨慎。
- 疫苗诱导的假阳性诊断偏倚在基线血清阴性个体中更明显。
核心结论
- 接种CYD-TDV者常规监测中获得的IgM和IgG数据解读需谨慎;在CYD-TDV已在多个登革热流行国家获批的背景下,亟需新的实用、登革热特异性诊断算法。
研究设计与样本
- 对两项III期、安慰剂对照CYD-TDV效力研究(涉及亚洲和拉丁美洲10个国家≥31000名2-16岁儿童)主动监测期(首次研究注射后25个月)内发生的发热事件进行事后汇总分析。
- 病毒学确诊登革热定义为登革热非结构蛋白1抗原或登革热聚合酶链反应检测阳性。
- 可能登革热血清学定义为:急性期或恢复期样本IgM阳性,或急性期样本IgG阳性且急性期与恢复期样本间IgG升高≥4倍。
主要发现
- 病毒学确诊登革热1284例(CYD-TDV组575例,安慰剂组709例),其他发热事件17673例(CYD-TDV组11668例,安慰剂组6005例)。
- 与病毒学确诊登革热相比,可能登革热定义的敏感性为93.1%,特异性为77.2%。
- 总体阳性预测值为22.9%,阴性预测值为99.5%,反映在包含接种队列的人群中正确确认可能登革热的概率要低得多。
- 接种疫苗诱导的假阳性诊断偏倚在基线血清阴性个体中更为明显。
关键数值与推荐
- 可能登革热血清学定义:急性期或恢复期样本IgM阳性,或急性期样本IgG阳性且急性期与恢复期样本间IgG升高≥4倍。
- 病毒学确诊登革热定义:登革热非结构蛋白1抗原或登革热聚合酶链反应检测阳性。
临床怎么用
- 接种CYD-TDV者常规监测中获得的IgM和IgG数据解读需谨慎。
- 亟需新的实用、登革热特异性诊断算法。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We previously reported that vaccination with the tetravalent dengue vaccine (CYD-TDV; Dengvaxia) may bias the diagnosis of dengue based on immunoglobulin M (IgM) and immunoglobulin G (IgG) assessments. METHODS: We undertook a post hoc pooled analysis of febrile episodes that occurred during the active surveillance phase (the 25 months after the first study injection) of 2 pivotal phase III, placebo-controlled CYD-TDV efficacy studies that involved ≥31000 children aged 2-16 years across 10 countries in Asia and Latin America. Virologically confirmed dengue (VCD) episode was defined with a positive test for dengue nonstructural protein 1 antigen or dengue polymerase chain reaction. Probable dengue episode was serologically defined as (1) IgM-positive acute- or convalescent-phase sample, or (2) IgG-positive acute-phase sample and ≥4-fold IgG increase between acute- and convalescent-phase samples. RESULTS: There were 1284 VCD episodes (575 and 709 in the CYD-TDV and placebo groups, respectively) and 17673 other febrile episodes (11668 and 6005, respectively). Compared with VCD, the sensitivity and specificity of probable dengue definition were 93.1% and 77.2%, respectively. Overall positive and negative predictive values were 22.9% and 99.5%, respectively, reflecting the much lower probability of correctly confirming probable dengue in a population including a vaccinated cohort. Vaccination-induced bias toward false-positive diagnosis was more pronounced among individuals seronegative at baseline. CONCLUSIONS: Caution will be required when interpreting IgM and IgG data obtained during routine surveillance in those vaccinated with CYD-TDV. There is an urgent need for new practical, dengue-specific diagnostic algorithms now that CYD-TDV is approved in a number of dengue-endemic countries. CLINICAL TRIALS REGISTRATION: NCT01373281 and NCT01374516.
引用
- Plennevaux E, Moureau A, Arredondo-García JL, et al. Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials. Clin Infect Dis. 2018. PMID: 29300876. doi:10.1093/cid/cix966
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。